Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 17/20 | 1.00 |
| ▸ | CCR1 | P32246 | 1/20 | 0.60 |
| ▸ | CCR5 | P51681 | 1/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17557249 | 0.81 | CCR2 (0.68) | CCR2NAAA | |
| SCHEMBL17557250 | 0.81 | CCR2 (0.68) | CCR2NAAA | |
| SCHEMBL16071259 | 0.81 | CCR2 (0.68) | CCR2NAAA | |
| SCHEMBL13006179 | 0.79 | CCR2 (1.00) | CCR2 | |
| SCHEMBL3319001 | 0.79 | CCR2 (1.00) | CCR2 | |
| SCHEMBL3743288 | 0.76 | CCR2 (0.61) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL27476000 | 0.76 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4NOD1 | |
| SCHEMBL8378854 | 0.76 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4NOD1 | |
| SCHEMBL8379050 | 0.76 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4NOD1 | |
| SCHEMBL28421652 | 0.76 | CCR2 (0.61) | CCR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | claimed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | claimed |
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | disclosed |
| EP-1781299-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194541-A1 | Anti-Inflammatory Agents | TNF, IL1RN, FPR1 | CCR2 96/4885CCR1 137/4885CCR5 126/4885 |
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | CCR2 121/4885CCR1 160/4885CCR5 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.